Annual report pursuant to Section 13 and 15(d)

SIGNIFICANT CONCENTRATIONS

v2.4.0.6
SIGNIFICANT CONCENTRATIONS
 12 Months Ended
Dec. 31, 2011
SIGNIFICANT CONCENTRATIONS  
SIGNIFICANT CONCENTRATIONS

3. SIGNIFICANT CONCENTRATIONS

        For the year ended December 31, 2011, Merck Serono and BerGenBio accounted for 89% and 11% of our revenues, respectively. For the year ended December 31, 2010, AZ accounted for 100% of our revenues. For the year ended December 31, 2009, Daiichi accounted for 100% of our revenues. At December 31, 2011 and 2010, we had no accounts receivable. We do not require collateral or other security for accounts receivable.